BioCorRx Provides Business Update for the Full Year Ended 2017
April 06, 2018 07:30 ET
|
BioCorRx Inc
ANAHEIM, CA, April 06, 2018 (GLOBE NEWSWIRE) -- BioCorRx Inc. (OTCQB: BICX) (the "Company"), a developer and provider of advanced solutions in the treatment of alcohol and opioid addictions, today...
BioCorRx Comments on President Donald J. Trump’s Initiative to Stop Opioid Abuse
March 20, 2018 10:40 ET
|
BioCorRx Inc
ANAHEIM, CA, March 20, 2018 (GLOBE NEWSWIRE) -- BioCorRx Inc. (OTCQB: BICX) (the "Company"), a developer and provider of advanced solutions in the treatment of alcohol and opioid addictions,...
BioCorRx Provides Update on New Weight Management Program
March 15, 2018 08:08 ET
|
BioCorRx Inc
ANAHEIM, CA, March 15, 2018 (GLOBE NEWSWIRE) -- BioCorRx Inc. (OTCQB: BICX) (the "Company"), a developer and provider of advanced solutions in the treatment of alcohol and opioid addictions, today...
BioCorRx Schedules Business Update Conference Call
March 01, 2018 07:30 ET
|
BioCorRx Inc
ANAHEIM, CA, March 01, 2018 (GLOBE NEWSWIRE) -- BioCorRx Inc. (OTCQB: BICX) (the "Company"), a developer and provider of advanced solutions in the treatment of alcohol and opioid addictions, today...
Dr. Joseph DeSanto and BioCorRx Recovery Program Participant Appear on the TV Show, The Doctors
February 15, 2018 08:00 ET
|
BioCorRx Inc
ANAHEIM, CA, Feb. 15, 2018 (GLOBE NEWSWIRE) -- BioCorRx Inc. (OTCQB: BICX) (the "Company"), a developer and provider of advanced solutions in the treatment of alcohol and opioid addictions, today...
BioCorRx Announces Results of Pre-IND meeting with FDA for Sustained Release Naltrexone Implant, BICX102
February 12, 2018 09:23 ET
|
BioCorRx Inc
505(b)(2) application plan acceptable per FDA Application will seek dual indications for opioid and alcohol use disorders ANAHEIM, CA, Feb. 12, 2018 (GLOBE NEWSWIRE) -- BioCorRx...
BioCorRx Extends Service Agreement with Dr. Balbir S. Brar as VP of Drug Development Following Pre-IND Meeting with the U.S. FDA
February 08, 2018 07:30 ET
|
BioCorRx, Inc.
ANAHEIM, CA, Feb. 08, 2018 (GLOBE NEWSWIRE) -- BioCorRx Inc. (OTC: BICX) (the "Company"), a developer and provider of advanced solutions in the treatment of alcohol and opioid addictions, today...
BioCorRx Completes Pre-IND Meeting with FDA; Reports Company to Move Forward with BICX102
January 26, 2018 07:30 ET
|
BioCorRx, Inc.
ANAHEIM, CA , Jan. 26, 2018 (GLOBE NEWSWIRE) -- BioCorRx Inc. (OTCQB: BICX) (the "Company"), a developer and provider of advanced solutions in the treatment of alcohol and opioid addictions, today...
BioCorRx CEO, Brady Granier, Appears on Fox & Friends to Discuss the Opioid Epidemic
January 02, 2018 07:30 ET
|
BioCorRx Inc
ANAHEIM, CA, Jan. 02, 2018 (GLOBE NEWSWIRE) -- BioCorRx Inc. (OTCQB: BICX) (the "Company"), a developer and provider of advanced solutions in the treatment of alcohol and opioid addictions, today...
BioCorRx Submits Pre-IND Package to FDA for its Naltrexone Implant, BICX102
December 19, 2017 07:30 ET
|
BioCorRx Inc
ANAHEIM, CA, Dec. 19, 2017 (GLOBE NEWSWIRE) -- BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of advanced solutions in the treatment of alcohol and opioid addictions, today...